ZNF556 serves as an immunological and prognostic biomarker in colon adenocacinoma.
4 affiliations
- 1Department of General Surgery, Renhe Hospital, Baoshan District, Shanghai, 200431, China.
- 2Department of Outpatient, Sitang Community Health Service Center, Baoshan District, Shanghai, China. [email protected].
- 3Department of General Surgery, Renhe Hospital, Baoshan District, Shanghai, 200431, China. [email protected].
- 4Department of General Surgery, Renhe Hospital, Baoshan District, Shanghai, 200431, China. [email protected].
Abstract
Objectives
Colon adenocarcinoma (COAD) is one of the most common and deadliest digestive tract malignancies, but its diagnostic and prognostic markers still need further exploration as targets for risk stratification and treatment response.Methods
COAD cohorts were retrieved from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases. Differences in gene expression were analyzed using relevant R packages, followed by gene function enrichment analysis and Weighted Gene Co-expression Network Analysis (WGCNA). Next, the Kaplan-Meier method and LASSO regression analysis were employed to screen for prognostic signature genes associated with the survival of COAD patients. Furthermore, comprehensive analyses were conducted to assess the role of this signature gene in immunomodulation and genetic mutation. Single-cell RNA sequencing (scRNA-seq) analyses were performed using the GSE166555 dataset. Additionally, CCK-8, colony formation, wound healing and Transwell assays were used to evaluate the biological functions of the signature gene in COAD cells.Results
Differential expression analysis and WGCNA led to the identification of 156 candidate genes, which were primarily enriched in functional pathways including the cell cycle, P53 signaling pathway, and cellular senescence. Subsequently, LASSO regression combined with survival analysis screened out ZNF556 as a characteristic prognostic gene for COAD. The expression level of ZNF556 correlates with the infiltration of plasma cells, mast cells, and monocytes, and is further associated with the expression of multiple immune checkpoint genes. Additionally, gene mutation analysis revealed a significant correlation between mutant TP53 and ZNF556 expression. ScRNA-seq analysis further indicated that, in the context of COAD, ZNF556 may exert a key regulatory role in the differentiation of epithelial cells, thereby facilitating tumor initiation and progression. Furthermore, subsequent experiments confirmed the cancer-promoting effect of ZNF556, whose expression was positively regulated by mutant TP53.Conclusion
ZNF556 was highly up-regulated in COAD tissues, with high expression correlating with poor prognosis and difference in TIICs. It functions as a diagnostic, immunological and prognostic biomarker for COAD, and a potential therapeutic target.
Related
- BRIX1 Promotes Hepatocellular Carcinoma Progression via the MAPK/ERK Pathway and Serves as a Prognostic Biomarker
- AKNA serves as a prognostic biomarker and restrains endometrial cancer progression via STING activation and macrophage reprogramming
- ADAM19 Promotes EMT-Related Changes and Serves as a Prognostic Marker in Circulating Tumor Cells of Renal Cell Carcinoma.
- LncRNA RASAL2-AS1 serves as a potential biomarker for prognosis and regulates cellular processes via the miR-590-5p/PDCD5 axis and Wnt/β-catenin pathway in cervical cancer
- Upregulation of miR-200b-3p serves as a diagnostic biomarker for coronary atherosclerosis and regulates the oxidized low-density lipoprotein cholesterol-induced dysfunction of vascular smooth muscle cells
BibTeX
@article{huang2026znf556,
title = {{ZNF556 serves as an immunological and prognostic biomarker in colon adenocacinoma.}},
author = {Cheng Huang and Shidong Feng and Hui Yi and Wenqian Tao and Yue Li and Zhiwei Liao},
journal = {BMC cancer},
year = {2026},
month = jul,
doi = {10.1186/s12885-026-16596-w},
url = {https://europepmc.org/article/MED/42928156},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - ZNF556 serves as an immunological and prognostic biomarker in colon adenocacinoma.
AU - Cheng Huang
AU - Shidong Feng
AU - Hui Yi
AU - Wenqian Tao
AU - Yue Li
AU - Zhiwei Liao
PY - 2026
DA - 2026/07/29
JO - BMC cancer
DO - 10.1186/s12885-026-16596-w
UR - https://europepmc.org/article/MED/42928156
AB - Objectives Colon adenocarcinoma (COAD) is one of the most common and deadliest digestive tract malignancies, but its diagnostic and prognostic markers still need further exploration as targets for risk stratification and treatment response.Methods COAD cohorts were retrieved from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases. Differences in gene expression were analyzed using relevant R packages, followed by gene function enrichment analysis and Weighted Gene Co-expression Network Analysis (WGCNA). Next, the Kaplan-Meier method and LASSO regression analysis were employed to screen for prognostic signature genes associated with the survival of COAD patients. Furthermore, comprehensive analyses were conducted to assess the role of this signature gene in immunomodulation and genetic mutation. Single-cell RNA sequencing (scRNA-seq) analyses were performed using the GSE166555 dataset. Additionally, CCK-8, colony formation, wound healing and Transwell assays were used to evaluate the biological functions of the signature gene in COAD cells.Results Differential expression analysis and WGCNA led to the identification of 156 candidate genes, which were primarily enriched in functional pathways including the cell cycle, P53 signaling pathway, and cellular senescence. Subsequently, LASSO regression combined with survival analysis screened out ZNF556 as a characteristic prognostic gene for COAD. The expression level of ZNF556 correlates with the infiltration of plasma cells, mast cells, and monocytes, and is further associated with the expression of multiple immune checkpoint genes. Additionally, gene mutation analysis revealed a significant correlation between mutant TP53 and ZNF556 expression. ScRNA-seq analysis further indicated that, in the context of COAD, ZNF556 may exert a key regulatory role in the differentiation of epithelial cells, thereby facilitating tumor initiation and progression. Furthermore, subsequent experiments confirmed the cancer-promoting effect of ZNF556, whose expression was positively regulated by mutant TP53.Conclusion ZNF556 was highly up-regulated in COAD tissues, with high expression correlating with poor prognosis and difference in TIICs. It functions as a diagnostic, immunological and prognostic biomarker for COAD, and a potential therapeutic target.
SN - 1471-2407
ER -